Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Treating diabetic retinopathy (DR ... Pre-clinical studies show that after treatment with NG004, the retinal vasculature of animals with retinopathy has a structure very similar to that of ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

Diabetic retinopathy (DR) is an important cause of avoidable blindness worldwide. Seventy percent of diabetes occur in low and lower-middle income countries. Clinical practice guidelines for the ...

Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and ...

According to Future Market Insight, the global diabetic retinopathy market is likely to reach USD 15.50 billion by 2033, registering a CAGR of 5.8%. This is a significant rise from the estimated value ...

Medically reviewed by Bryan M. Wolynski, OD Blurry vision can be an early warning sign of diabetes. It's also a sign of ...

The possible treatment options will depend largely on the type of diabetic retinopathy one has been diagnosed with and its associated severity. Usually, the treatment for this condition is aimed ...